Low molecular weight precursor applicable for Alzheimer disease drugs synthesis (AChE and BChE inhibition, BACE inhibition, antioxidant properties and in silico modulation)

Journal of Applied Biomedicine

Volumn 12, Issue 4, 2014, Pages 285-290

  Drtinova, Lucie ^a   Dobes, Petr ^b   Pohanka, Miroslav ^a,c  

^a UNIVERSITY OF DEFENCE   (Czech Republic)

^b MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

^c Karel English College in Brno   (Czech Republic)

Author keywords

Acetylcholinesterase; Alzheimer disease; Betasecretase; Inhibition; Neurodegeneration

Indexed keywords

7 METHOXYTACRINE; ACETYLCHOLINESTERASE; ACETYLCYSTEINE; ACRIDINE; BETA SECRETASE; BETA SECRETASE INHIBITOR; CHINOLINE; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; HUPERZINE A; INDOLE; ISOQUINOLINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PIPERIDINE; PYRIDINE; PYRIDOXINE B6; RIVASTIGMINE; TACRINE; TROLOX C; TRYPTAMINE; TRYPTOPHAN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANTIOXIDANT ACTIVITY; ARTICLE; COMPUTER MODEL; CONTROLLED STUDY; DPPH RADICAL SCAVENGING ASSAY; DRUG DEVELOPMENT; DRUG STRUCTURE; DRUG SYNTHESIS; EC50; ENZYME INHIBITION; IC50; MOLECULAR DOCKING; MOLECULAR WEIGHT;

EID: 84925988858     PISSN: 1214021X     EISSN: 12140287     Source Type: Journal    
DOI: 10.1016/j.jab.2014.01.010     Document Type: Article

References (29)

1. Akwa, Y., Allain, H., Bentue, Ferrer, D., Berr, C., Bordet, R., Geerts, H., Nieoullon An Onteniente, B., Vercelleto, M., 2005. Neuroprotection and neurodegenerative diseases: from biology to clinical practice. Alzheimer Dis. Assoc. Disord. 19, 226-239.
2. Alzheimer's Association, 2010, 2010. Alzheimer's disease facts and figures. Alzheimer Dement. 6, 158-194.
3. Bai, D., 2007. Development of huperzine A and B for treatment of Alzheimer's disease. Pure Appl. Chem. 79, 469-479.
4. Bailey, J., Ray, B., Greig, N., Lahiri, D., 2011. Rivastigmine lowers Ab and increases sAPPa levels, which parallel elevated synaptic markers and metabolic activity in degenerating primary rat neurons. PLOS ONE 6, e21954.
5. Barak, D., Kronman, C., Ordentlich, A., Ariel, N., Bromberg, A., Marcus, D., Lazar, A., Velan, B., Shafferman, A., 1994. Acetylcholinesterase peripheral anionic site degeneracy by amino acid arrays sharing a common core. J. Biol. Chem. 269, 6296-6305.
6. Blennow, K., de Leon, M.J., Zetterberg, H., 2006. Alzheimer's disease. Lancet 368, 387-403.
7. Bores, G.M., Huger, F.P., Petko, W., Mutlib, A.E., Camacho, F., Rush, D.K., Selk, D.E., Wolf, V., Kosley Jr., R.W., Davis, L., Vargas, H.M., 1996. Pharmacological evaluation of novel Alzheimer's disease therapeutics: acetylcholinesterase inhibitors related to galantamine. J. Pharmacol. Exp. Ther. 277, 728738.
8. Darvesh, S., Hopkins, D.A., Geula, C., 2003. Neurobiology of butyrylcholinesterase. Nat. Rev. Neurosci. 4, 131-138.
9. Farris, W., Mansourian, S., Chang, Y., Lindsley, L., Eckman, E.A., Frosch, M.P., Eckman, C.B., Tanzi, R.E., Selkoe, D.J., Guenette, S., 2003. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein and the beta-amyloid precursor protein intracellular domain in vivo. Proc. Natl. Acad. Sci. 100, 4162-4167.
10. Giacobini, E., 2003. Cholineterases: new roles in brain function and in Azheimer's disease. Neurochem. Res. 28, 515-522.
11. Hong, L., Turner, R.T.I., Koelsch, G., Ghosh, A.K., Tang, J., 2002. Memapsin 2 (β-secretase) as a therapeutic target. Biochem. Soc. Trans. 30, 530-534.
12. Koellner, G., Kryger, G., Millard, C.B., Silman, I., Sussman, J.L., Steiner, T., 2000. Active-site gorge and buried water molecules in crystal structures of acetylcholinesterase from Torpedo Californica. J. Mol. Biol. 296, 713-735.
13. Ma, X., Gang, D.R., 2004. The Lycopodium alkaloids. Nat. Prod. Rep. 21, 752-772.
14. Mancini, F., Naldi, M., Cavrini, V., Andrisano, V., 2007. Multiwell fluorometric a colorimetric microassays for the evaluation of β-secretase (BACE-1) inhibitors. Anal. Bioanal. Chem. 388, 1175-1183.
15. Mesulam, M., Geula, C., 1994. Butyrylcholinesterase reactivity differentiates the amyloid plaques of aging from those of dementia. Am. Neurol. 36, 722-727.
16. Mihara, M., Ohnishi, A., Tomono, Y., Hasegawa, J., Shimamura, Y., Yamazaki, K., Morishita, N., 1993. Pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy male volunteers. Int. J. Clin. Pharmacol. Ther. Toxicol. 31, 223-229.
17. Mueller, S.G., Weiner, M.W., Thal, L.J., Petersen, R.C., Jack, C.R., Jagust, W., Trojanowski, J.Q., Toga, A.W., Beckett, L., 2005. The Alzheimer's disease neuroimaging initiative. Neuroimag. Clin. N. Am. 15, 869-877.
18. Nicholet, Y., Lockridge, O., Masson, P., Fontecilla-Camps, J.C., Nachon, F., 2003. Crystal structure of human butyrylcholinesterase and of its complexes with substrate and products. J. Biol. Chem. 278, 41141-41147.
19. Nieoullon, A., 2010. Acetylcholinesterase inhibitors in Alzheimer's disease: further comments on their mechanisms of action and therapeutic consequences. Psychol. Neurosychiatr. Vieil. 8, 123-131.
20. Pohanka, M., 2011. Cholinesterases, a target of pharmacology and toxicology. Biomed. Pap. 155, 219-223.
21. Pohanka, M., 2012. Acetylcholinesterase inhibitors: a patent review (2008-present). Expert Opin. Ther. Pat. 22, 871-886.
22. Pohanka, M., 2013. Alzheimer's disease and oxidative stress: a review. Curr. Med. Chem. 21, 356-364.
23. Pohanka, M., Drtinova, L., 2013. Spectrophotometric methods based on 2,6-dichloroindophenol acetate and indoxylacetate for butyrylcholinesterase activity assay in plasma. Talanta 106, 281-285.
24. Selkoe, D.J., 2000. The origins of Alzheimer disease: a is for amyloid. JAMA 283, 1615-1617.
25. Sugimoto, H., Iimura, Y., Yamanishi, Y., Yamatsu, K., 1995. Synthesis and structure-activity relationships of aceylcholinesterase inhibitors: 1-benzyl-4-[(5,6-dimethoxy-1-oxoindan-2-yl)methyl]piperidine hydrochloride and related compounds. J. Med. Chem. 38, 4821-4829.
26. Wang, R., Tang, X.C., 2005. Neuroprotective effects of huperzine A. Neurosignals 14, 71-82.
27. Yan, A., Wang, K., 2012. Quantitative structure and bioactivity relationship study on human acetylcholinesterase inhibitors. Bioorg. Med. Chem. Lett. 22, 3336-3342.
28. Zanetti, O., Solerte, S.B., Cantoni, F., 2009. Life expectancy in Alzheimer's disease (AD). Arch. Gerontol. Geriatr. 49, 237-243.
29. Zhang, H.Y., Yan, H., Tang, X.C., 2008. Non-cholinergic effects of huperzine A: beyond inhibition of acetylcholinesterase. Cell. Mol. Neurobiol. 28, 173-183.